Patents by Inventor Elizabeth Sally Ward
Elizabeth Sally Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230390413Abstract: Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.Type: ApplicationFiled: May 16, 2023Publication date: December 7, 2023Applicants: THE TEXAS A&M UNIVERSITY SYSTEM, Board of Regents of the University of Texas SystemInventors: Elizabeth Sally WARD OBER, Raimund Johannes OBER, Jeffrey Che-Wei KANG, Wei SUN, Ran LI
-
Patent number: 11690919Abstract: Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.Type: GrantFiled: January 17, 2018Date of Patent: July 4, 2023Assignees: The Texas A&M University System, Board of Regents of the University of Texas SystemInventors: Elizabeth Sally Ward Ober, Raimund Johannes Ober, Jeffrey Che-Wei Kang, Wei Sun, Ran Li
-
Publication number: 20230087965Abstract: The present disclosure includes a fusion protein, called a “Seldeg”, including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.Type: ApplicationFiled: September 8, 2022Publication date: March 23, 2023Inventors: Elizabeth Sally Ward OBER, Venkata Siva Charan Devanaboyina, Raimund Johannes Ober
-
Patent number: 11459396Abstract: The present disclosure includes a fusion protein, called a “Seldeg”, including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.Type: GrantFiled: December 1, 2017Date of Patent: October 4, 2022Assignee: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Elizabeth Sally Ward Ober, Venkata Siva Charan Devanaboyina, Raimund Johannes Ober
-
Publication number: 20200031948Abstract: The present disclosure includes a fusion protein, called a “Seldeg”, including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.Type: ApplicationFiled: December 1, 2017Publication date: January 30, 2020Applicant: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Elizabeth Sally Ward OBER, Venkata Siva Charan DEVANABOYINA, Raimund Johannes OBER
-
Publication number: 20190381183Abstract: Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.Type: ApplicationFiled: January 17, 2018Publication date: December 19, 2019Applicant: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Elizabeth Sally WARD OBER, Raimund Johannes OBER, Jeffrey Che-Wei KANG, Wei SUN, Ran LI
-
Patent number: 9562100Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: June 20, 2014Date of Patent: February 7, 2017Assignees: MedImmune LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
-
Publication number: 20140377181Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: ApplicationFiled: June 20, 2014Publication date: December 25, 2014Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLCInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
-
Patent number: 8795661Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: May 20, 2013Date of Patent: August 5, 2014Assignees: MedImmune, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
-
Publication number: 20130272964Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: ApplicationFiled: May 20, 2013Publication date: October 17, 2013Inventors: WILLIAM DALL'ACQUA, LESLIE S. JOHNSON, ELIZABETH SALLY WARD OBER
-
Patent number: 8475792Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: October 24, 2012Date of Patent: July 2, 2013Assignees: MedImmune, LLC, Board of Regents, The Texas University SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
-
Patent number: 8323962Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: July 27, 2011Date of Patent: December 4, 2012Assignees: MedImmune, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Publication number: 20110311454Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: ApplicationFiled: July 27, 2011Publication date: December 22, 2011Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLCInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 8012476Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: January 21, 2010Date of Patent: September 6, 2011Assignees: MedImmune, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Publication number: 20100189718Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: ApplicationFiled: January 21, 2010Publication date: July 29, 2010Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 7704497Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: January 3, 2007Date of Patent: April 27, 2010Assignees: MedImmune, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 7670600Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: April 3, 2006Date of Patent: March 2, 2010Assignees: MedImmine, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 7306907Abstract: The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis or catalysis.Type: GrantFiled: November 8, 2002Date of Patent: December 11, 2007Assignee: Cambridge Antibody Technology LimitedInventors: Gregory Paul Winter, Elizabeth Sally Ward, Detlef Güssow
-
Patent number: 7083784Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: December 12, 2001Date of Patent: August 1, 2006Assignee: MedImmune, Inc.Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 6821505Abstract: Disclosed are recombinant vectors encoding immunoglobulin-like domains and portions thereof, such as antibody Fc-hinge fragments, subfragments and mutant domains with extended biological half lives. Methods of producing large quantities of such domains, heterodimers, and fusion proteins following expression by host cells are also reported. Described are antibody Fc and Fc-hinge domains, which have the same in vivo stability as intact antibodies; and domains engineered to have increased in vivo half lives. These DNA constructs and protein domains will be useful as templates for in vitro mutagenesis and high resolution structural studies; for immunization and vaccination; and for the production of recombinant antibodies or chimeric proteins with increased stability and longevity for therapeutic and diagnostic uses.Type: GrantFiled: August 20, 2001Date of Patent: November 23, 2004Assignee: Board of Regents, The University of Texas SystemInventor: Elizabeth Sally Ward